Lepzacitinib
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases[1].
Product Specifications
CAS Number
[2321488-47-3]
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lepzacitinib.html
Purity
99.30
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCOC(C1=CN=C(NC=C2)C2=C1N[C@H]3CN(CCC3)C(CC#N)=O)=O
Molecular Formula
C18H21N5O3
Molecular Weight
355.39
References & Citations
[1]Anderson, et al. Preparation of substituted pyrrolopyridine compounds as JAK inhibitors. World Intellectual Property Organization, WO2019090158 A1 2019-05-09.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7011756-01 0.02 mg
Recombinant Yersinia enterocolitica serotype O:8 / biotype 1B Cardiolipin synthase (cls)
Ask
View Details MBS7011756-02 0.1 mg
Recombinant Yersinia enterocolitica serotype O:8 / biotype 1B Cardiolipin synthase (cls)
Ask
View Details MBS7011756-03 5x 0.1 mg
Recombinant Yersinia enterocolitica serotype O:8 / biotype 1B Cardiolipin synthase (cls)
Ask
View Details 
MBS6282554-01 0.2 mL
CCNY, ID (CCNY, C10orf9, CBCP1, CFP1, Cyclin-Y, Cyclin box protein 1, Cyclin fold protein 1, cyclin-X) (APC)
Ask
View Details